Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation

Nature Neuroscience volume 16, pages 1618–1626 (2013)Cite this article

Subjects

Abstract

Microglia are brain macrophages and, as such, key immune-competent cells that can respond to environmental changes. Understanding the mechanisms of microglia-specific responses during pathologies is hence vital for reducing disease burden. The definition of microglial functions has so far been hampered by the lack of genetic in vivo approaches that allow discrimination of microglia from closely related peripheral macrophage populations in the body. Here we introduce a mouse experimental system that specifically targets microglia to examine the role of a mitogen-associated protein kinase kinase kinase (MAP3K), transforming growth factor (TGF)-β-activated kinase 1 (TAK1), during autoimmune inflammation. Conditional depletion of TAK1 in microglia only, not in neuroectodermal cells, suppressed disease, significantly reduced CNS inflammation and diminished axonal and myelin damage by cell-autonomous inhibition of the NF-κB, JNK and ERK1/2 pathways. Thus, we found TAK1 to be pivotal in CNS autoimmunity, and we present a tool for future investigations of microglial function in the CNS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Characterization of the Cx3cr1Cre line in the CNS.
Figure 2: Long-term microglial specificity in Cx3cr1CreER mice.
Figure 3: Microglia-restricted absence of TAK1 abolishes autoimmune inflammation in the CNS.
Figure 4: Reduced CNS damage and immune suppression in Cx3cr1CreER:Tak1fl/fl mice.
Figure 5: Diminished MHC class II expression in Cx3cr1CreER:Tak1fl/fl mice during EAE.
Figure 6: Microglia-specific TAK1 controls cell-intrinsic activation of NF-κBp65.

Similar content being viewed by others

References

  1. Ransohoff, R.M. & Perry, V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119–145 (2009).

    Article  CAS  PubMed  Google Scholar 

  2. Hanisch, U.K. Microglia as a source and target of cytokines. Glia 40, 140–155 (2002).

    Article  PubMed  Google Scholar 

  3. Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90 (2012).

    Article  CAS  PubMed  Google Scholar 

  5. Prinz, M. & Mildner, A. Microglia in the CNS: immigrants from another world. Glia 59, 177–187 (2011).

    Article  PubMed  Google Scholar 

  6. Kierdorf, K. et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 16, 273–280 (2013).

    Article  CAS  PubMed  Google Scholar 

  7. Ransohoff, R.M. & Cardona, A.E. The myeloid cells of the central nervous system parenchyma. Nature 468, 253–262 (2010).

    Article  CAS  PubMed  Google Scholar 

  8. Steinman, L., Martin, R., Bernard, C., Conlon, P. & Oksenberg, J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 25, 491–505 (2002).

    Article  CAS  PubMed  Google Scholar 

  9. Heppner, F.L. et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11, 146–152 (2005).

    Article  CAS  PubMed  Google Scholar 

  10. Becher, B., Durell, B.G., Miga, A.V., Hickey, W.F. & Noelle, R.J. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193, 967–974 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Schwartz, M. & Moalem, G. Beneficial immune activity after CNS injury: prospects for vaccination. J. Neuroimmunol. 113, 185–192 (2001).

    Article  CAS  PubMed  Google Scholar 

  12. Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H. & Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 53, 292–304 (2003).

    Article  CAS  PubMed  Google Scholar 

  13. Tremblay, M.È., Lowery, R.L. & Majewska, A.K. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 8, e1000527 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Paolicelli, R.C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458 (2011).

    Article  CAS  PubMed  Google Scholar 

  15. Marín-Teva, J.L. et al. Microglia promote the death of developing Purkinje cells. Neuron 41, 535–547 (2004).

    Article  PubMed  Google Scholar 

  16. Derecki, N.C. et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105–109 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Pfrieger, F.W. & Slezak, M. Genetic approaches to study glial cells in the rodent brain. Glia 60, 681–701 (2012).

    Article  PubMed  Google Scholar 

  18. Sakurai, H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 33, 522–530 (2012).

    Article  CAS  PubMed  Google Scholar 

  19. Adhikari, A., Xu, M. & Chen, Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26, 3214–3226 (2007).

    Article  CAS  PubMed  Google Scholar 

  20. Karin, M. & Gallagher, E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol. Rev. 228, 225–240 (2009).

    Article  CAS  PubMed  Google Scholar 

  21. Bettermann, K. et al. TAK1 suppresses a NEMO-dependent but NF-κB-independent pathway to liver cancer. Cancer Cell 17, 481–496 (2010).

    Article  CAS  PubMed  Google Scholar 

  22. Sato, S. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087–1095 (2005).

    Article  CAS  PubMed  Google Scholar 

  23. Tang, M. et al. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 205, 1611–1619 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Jung, S. et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell Biol. 20, 4106–4114 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cardona, A.E. et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9, 917–924 (2006).

    Article  CAS  PubMed  Google Scholar 

  26. Kim, K.W. et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 118, e156–e167 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Geissmann, F., Jung, S. & Littman, D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71–82 (2003).

    Article  CAS  PubMed  Google Scholar 

  28. Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79–91 (2013).

    Article  CAS  PubMed  Google Scholar 

  29. Dighe, A.S. et al. Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. Immunity 3, 657–666 (1995).

    Article  CAS  PubMed  Google Scholar 

  30. Town, T. et al. Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14, 681–687 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W. & Rossi, F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10, 1538–1543 (2007).

    Article  CAS  PubMed  Google Scholar 

  32. Mildner, A. et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 10, 1544–1553 (2007).

    Article  CAS  PubMed  Google Scholar 

  33. Raasch, J. et al. IκB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-κB in the central nervous system. Brain 134, 1184–1198 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  34. van Loo, G. et al. Inhibition of transcription factor NF-κB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 7, 954–961 (2006).

    Article  CAS  PubMed  Google Scholar 

  35. Ulvestad, E. et al. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J. Leukoc. Biol. 56, 732–740 (1994).

    Article  CAS  PubMed  Google Scholar 

  36. Sheppard, K.-A. et al. Transcriptional activation by NF-κB requires multiple coactivators. Mol. Cell Biol. 19, 6367–6378 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Mildner, A. et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132, 2487–2500 (2009).

    Article  PubMed  Google Scholar 

  38. Flügel, A., Bradl, M., Kreutzberg, G.W. & Graeber, M.B. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J. Neurosci. Res. 66, 74–82 (2001).

    Article  PubMed  Google Scholar 

  39. Ford, A.L., Goodsall, A.L., Hickey, W.F. & Sedgwick, J.D. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J. Immunol. 154, 4309–4321 (1995).

    CAS  PubMed  Google Scholar 

  40. Matyszak, M.K. et al. Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur. J. Immunol. 29, 3063–3076 (1999).

    Article  CAS  PubMed  Google Scholar 

  41. Wang, Y. et al. Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function. Proc. Natl. Acad. Sci. USA 109, E343–E352 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Rajasekaran, K. et al. Transforming growth factor-β-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production. J. Biol. Chem. 286, 31213–31224 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ajibade, A.A. et al. TAK1 negatively regulates NF-κB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 36, 43–54 (2012).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Zehntner, S.P., Brisebois, M., Tran, E., Owens, T. & Fournier, S. Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease. FASEB J. 17, 1910–1912 (2003).

    Article  CAS  PubMed  Google Scholar 

  45. Siao, C.J., Fernandez, S.R. & Tsirka, S.E. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J. Neurosci. 23, 3234–3242 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Rong, L.L. et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J. 18, 1818–1825 (2004).

    Article  CAS  PubMed  Google Scholar 

  47. Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211–220 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Prinz, M. & Hanisch, U.K. Murine microglial cells produce and respond to interleukin-18. J. Neurochem. 72, 2215–2218 (1999).

    Article  CAS  PubMed  Google Scholar 

  49. Mildner, A. et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31, 11159–11171 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kierdorf, K. et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 16, 273–280 (2013).

    Article  CAS  PubMed  Google Scholar 

  51. Raasch, J. et al. IκB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-κB in the central nervous system. Brain 134, 1184–1198 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  52. Clavijo, P.E. & Frauwirth, K.A. Anergic CD8+ T lymphocytes have impaired NF-κB activation with defects in p65 phosphorylation and acetylation. J. Immunol. 188, 1213–1221 (2012).

    Article  CAS  PubMed  Google Scholar 

  53. Bond, D., Primrose, D.A. & Foley, E. Quantitative evaluation of signaling events in Drosophila S2 cells. Biol. Proced. Online 10, 20–28 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Atif, F. et al. Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: the role of BDNF/TrkB/Erk1/2 signaling in neuroprotection. Neuropharmacology 67, 78–87 (2013).

    Article  CAS  PubMed  Google Scholar 

  55. Wolf, M.J. et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22, 91–105 (2012).

    Article  CAS  PubMed  Google Scholar 

  56. Dann, A. et al. Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat. Neurosci. 15, 98–106 (2012).

    Article  CAS  Google Scholar 

  57. Bettermann, K. et al. TAK1 suppresses a NEMO-dependent but NF-κB-independent pathway to liver cancer. Cancer Cell 17, 481–496 (2010).

    Article  CAS  PubMed  Google Scholar 

  58. Ngubo, M., Kemp, G. & Patterton, H.G. Nano-electrospray tandem mass spectrometric analysis of the acetylation state of histones H3 and H4 in stationary phase in Saccharomyces cerevisiae. BMC Biochem. 12, 34 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank M. Oberle, C. Fix and S. Gaupp for excellent technical assistance. Special thanks to M. Olschewski for help with the thorough statistical analysis of our data. M.P. was supported by the Bundesministerium für Bildung und Forschung–funded competence network of multiple sclerosis (KKNMS), the competence network of neurodegenerative disorders (KNDD), the Deutsche Forschungsgemeinschaft (SFB 992, FOR1336, PR 577/8-1), the Fritz-Thyssen Foundation, the Gemeinnützige Hertie Foundation (GHST) and Biogen Idec. P.F.M. was supported by an MD educational grant of the SFB620. M.H. was funded by the Helmholtz Foundation, the SFB-TR36, a European Research Council starting grant and the Helmholtz Alliance Preclinical Comprehensive Cancer Center. S.J. was supported by the Deutsche Forschungsgemeinschaft (FOR1336) and by the Israel Science Foundation.

Author information

Author notes

  1. Tobias Goldmann, Peter Wieghofer, Steffen Jung and Marco Prinz: These authors contributed equally to this work.

Authors and Affiliations

  1. Institute of Neuropathology, University of Freiburg, Freiburg, Germany

    Tobias Goldmann, Peter Wieghofer, Philippe F Müller, Stefanie M Brendecke, Katrin Kierdorf, Ori Staszewski, Moumita Datta & Marco Prinz

  2. Faculty of Biology, University of Freiburg, Freiburg, Germany

    Peter Wieghofer

  3. Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel

    Yochai Wolf, Diana Varol, Simon Yona & Steffen Jung

  4. Department of Internal Medicine III, University Hospital Rheinisch-Westfälische Technische Hochschule,

    Tom Luedde

  5. Aachen, Aachen, Germany

    Tom Luedde

  6. Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany

    Mathias Heikenwalder

  7. BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany

    Marco Prinz

Authors
  1. Tobias Goldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Wieghofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe F Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yochai Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diana Varol
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Simon Yona
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefanie M Brendecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katrin Kierdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ori Staszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Moumita Datta
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tom Luedde
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mathias Heikenwalder
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Steffen Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Marco Prinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

T.G., P.W., P.F.M., S.M.B., K.K., D.V., Y.W., O.S. and M.D. conducted experiments. S.Y. generated the transgenic mice. S.J., M.H. and T.L. contributed to the in vivo studies and provided mice or reagents. M.P. and S.J. supervised the project and wrote the manuscript.

Corresponding authors

Correspondence to Steffen Jung or Marco Prinz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Microglial rearrangement of individual conditional yfp and rfp reporter alleles in Cx3cr1CreER:R26-yfp:R26-rfp mice under different TAM administration routes.

(a) Breeding scheme of CX3CR1CreER animals with R26-yfp:R26-rfp indicator mice. (b) Flow cytometry analysis of the blood for YFP and RFP. For s.c. injections, mice received dosages of 10 mg on 4 consecutive days and were analyzed at day 14. For oral administration by gavage, mice received doses of 5 mg on 6 consecutive days and were analyzed at day 14. Results are representative of three independent experiments.

Supplementary Figure 2 Long term and stable microglia-specific gene activation in Cx3cr1CreER:R26-yfp mice.

Induction but subsequent progressive loss of cells harbouring gene rearrangements in peripheral myeloid cells (Ly6Clo monocytes, splenic CD4+ DCs) and tissue macrophages (Kupffer cells) but persistence of genomic modification in microglia. Representative flow cytometry data displaying different recombination efficacies in distinct myeloid cell types. Results are representative of two independent experiments.

Supplementary Figure 3 Microglia can be distinguished from infiltrating myeloid cells in Cx3cr1CreER:R26-yfp mice during autoimmune inflammation.

(a) Scheme of EAE induction in CX3CR1CreER:R26-yfp mice. (b) Spinal cord flow cytometric analysis reveals the presence of YFP+ microglia that can be separated from non-labelled myeloid cells from the blood during MOG35-55-induced CNS inflammation. One representative experiment out of two is shown. (c) Quantification thereof. Mean ± SEM per group are depicted. Results are representative of two independent experiments.

Supplementary Figure 4 Low gene recombination efficacy in microglia of LysMCre animals.

(a) Flow cytometry analysis of percoll gradient-isolated microglia from LysMCre:R26-yfp mice (left, Cre negative litter is shown as dotted line) and quantification thereof (right). Mean ± SEM per group are depicted. (B) Direct fluorescence microscopic visualization revealed few YFP-positive ramified cells (green) with typical microglial morphology and Iba-1 immunoreactivity (red) in some regions of the brain whereas most microglia were not YFP-positive (asterisks). Arrows point to double positive cells. Scale bar = 20 μm. (c) Semi-quantitative evaluation of YFP-Iba-1 double positive microglia in distinct regions of the CNS. Data are represented as mean ± SEM of three to four mice per group. (d) YFP-positive cells in different blood cell subsets. Data are represented as mean ± SEM of four to six mice per group.

Supplementary Figure 5 Limited target gene activation in microglia of CD11cCre animals.

(a) FACS analysis on isolated CD45loCD11b+ microglia in CD11cCre:R26-yfp mice (left, a Cre negative litter is depicted as dotted line) and quantification thereof (right). Mean ± SEM per group are shown. (b) Iba-1 (red) and YFP immunohistochemistry (green) in different regions of the brain in CD11cCre:R26-yfp mice. Asterisks indicate the localization of Iba1-positive cells. Scale bar = 20 μm. (c) Semi-quantitative evaluation of YFP-Iba-1 double positive microglia on histological slices in distinct regions of the CNS. Data are represented as mean ± SEM of at least three mice per group. (d) Percentage of YFP-positive cells in different blood cell subsets. Data are represented as mean ± SEM of five mice per group.

Supplementary Figure 6 Microglia-specific TAK1 is dispensable for normal CNS homeostasis.

Absence of any gross abnormalities within the brain (a) and spinal cord (b) in the absence of TAK1 in microglia. H&E staining revealed unaltered structures in the cortex and spinal cord in CX3CR1CreER:Tak1fl/fl mice four weeks after TAM injection into five to seven week old animals. Scale bars = 500 μm (overview) and 100 μm (detail). Middle panel: Iba-1 immunohistochemistry revealed no microglia clusters or malformed microglia (scale bars = 25 μm (overview) and 20 μm (detail)). Lower panel: GFAP immunohistochemistry exhibited no signs of astrogliosis in CX3CR1CreER:Tak1fl/fl animals.

Supplementary Figure 7 No signs of cell activation in microglia devoid of TAK1.

Microglia (Iba-1, green) in CX3CR1CreER:Tak1fl/fl animals do not express MHC class II or Lamp2 (red, scale bar = 25 μm). Inserts show double positive perivascular macrophages in the same sections as control.

Supplementary Figure 8 Impaired ERK, p38 and JNK activation in microglia in the CNS of Cx3cr1CreER:Tak1fl/fl mice with EAE 20 d post-immunization.

Frozen sections of lumbal spinal cords from microglia-specific CX3CR1CreER:Tak1fl/fl mice with EAE, stained for IB4 (red) for microglia with distinct processes and activated pERK1/2, pp38 or pJNK (green), respectively. Nuclei are stained with DAPI (4,6-diamidino-2-phenylindole; blue). Scale bar = 10 μm. Arrows highlight double positive microglia. Asterisks indicate an activated hematopoietic cell. Results are representative of two independent experiments.

Supplementary Figure 9 High gene recombination efficacy in primary microglia of Cx3cr1CreER mice.

(a) Scheme for the induction of recombination in primary microglia from CX3CR1CreER:R26-yfp animals. Hydroxy-tamoxifen (OH-TAM) was applied three days prior to analysis. (b) Primary microglia in CX3CR1CreER:R26-yfp mice were characterized by surface expression of CD45 and CD11b and concomitant YFP expression three days after OH-TAM application by FACS. The percentage of YFP+ microglia is indicated. A Cre negative littermate is shown as a grey line. (c) High gene recombination in primary microglia from CX3CR1CreER:R26-yfp individuals using immunohistochemistry for YFP (green), the microglia marker Iba-1 (red), DAPI (blue) after OH-TAM challenge. Virtually all microglia from CX3CR1CreER:R26-yfp mice were EYFP+ whereas no microglia were YFP+ in R26-yfp mice.

Supplementary Figure 10 Full-length western blot images of Figures 3a,c and 6d.

Supplementary Figure 11 Full-length images of Figure 6e.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–11 (PDF 20958 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldmann, T., Wieghofer, P., Müller, P. et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 16, 1618–1626 (2013). https://doi.org/10.1038/nn.3531

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nn.3531

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing